LeMaitre Vascular (NASDAQ:LMAT) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday.
Several other research firms also recently weighed in on LMAT. Roth Capital downgraded shares of LeMaitre Vascular from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $38.00 to $39.00 in a research report on Tuesday, October 2nd. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Wednesday, September 26th. Barrington Research raised shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a research report on Monday, October 8th. Canaccord Genuity dropped their target price on shares of LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating on the stock in a research report on Monday, October 8th. Finally, ValuEngine downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Saturday, October 6th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Hold” and an average target price of $35.86.
LeMaitre Vascular stock opened at $26.01 on Friday. The company has a market capitalization of $520.88 million, a PE ratio of 30.24, a PEG ratio of 2.17 and a beta of 1.00. LeMaitre Vascular has a fifty-two week low of $25.63 and a fifty-two week high of $41.28.
LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share for the quarter, hitting the consensus estimate of $0.21. The business had revenue of $24.17 million for the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a net margin of 20.52% and a return on equity of 18.07%. As a group, research analysts predict that LeMaitre Vascular will post 1.02 EPS for the current year.
In related news, Director Michael H. Thomas sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 30th. The shares were sold at an average price of $27.93, for a total transaction of $558,600.00. Following the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at $558,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.30% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in LMAT. Piedmont Investment Advisors LLC acquired a new stake in LeMaitre Vascular in the second quarter valued at approximately $119,000. Tower Research Capital LLC TRC lifted its stake in LeMaitre Vascular by 222.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,451 shares of the medical instruments supplier’s stock valued at $149,000 after acquiring an additional 3,072 shares during the last quarter. First Trust Advisors LP acquired a new stake in LeMaitre Vascular in the third quarter valued at approximately $214,000. Jane Street Group LLC acquired a new stake in LeMaitre Vascular in the second quarter valued at approximately $206,000. Finally, Quantitative Systematic Strategies LLC acquired a new stake in LeMaitre Vascular in the second quarter valued at approximately $263,000. 81.54% of the stock is currently owned by hedge funds and other institutional investors.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More: Conference Calls
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.